These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3093521)

  • 21. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for decreased luteinizing hormone-releasing hormone pulse frequency in men with selective elevations of follicle-stimulating hormone.
    Gross KM; Matsumoto AM; Southworth MB; Bremner WJ
    J Clin Endocrinol Metab; 1985 Jan; 60(1):197-202. PubMed ID: 3917266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Participation of endogenous opiates in regulation of the hypothalamic-pituitary-testicular axis in normal men.
    Delitala G; Giusti M; Mazzocchi G; Granziera L; Tarditi W; Giordano G
    J Clin Endocrinol Metab; 1983 Dec; 57(6):1277-81. PubMed ID: 6415088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
    Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal and clinical effects of ketoconazole in hirsute women.
    Martikainen H; Heikkinen J; Ruokonen A; Kauppila A
    J Clin Endocrinol Metab; 1988 May; 66(5):987-91. PubMed ID: 2966183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone differentially modulates gonadotropin subunit messenger ribonucleic acid responses to gonadotropin-releasing hormone pulse amplitude.
    Iliff-Sizemore SA; Ortolano GA; Haisenleder DJ; Dalkin AC; Krueger KA; Marshall JC
    Endocrinology; 1990 Dec; 127(6):2876-83. PubMed ID: 1701131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A preponderance of circulating basic isoforms is associated with decreased plasma half-life and biological to immunological ratio of gonadotropin-releasing hormone-releasable luteinizing hormone in obese men.
    Castro-Fernández C; Olivares A; Söderlund D; López-Alvarenga JC; Zambrano E; Veldhuis JD; Ulloa-Aguirre A; Méndez JP
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4603-10. PubMed ID: 11134115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
    Huhtaniemi I; Nikula H; Rannikko S
    J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The response of pituitary gonadotropes to a constant infusion of luteinizing hormone-releasing hormone (LHRH) in normal prepubertal and pubertal children and in children with abnormalities of sexual development.
    Reiter EO; Root AW; Duckett GE
    J Clin Endocrinol Metab; 1976 Aug; 43(2):400-11. PubMed ID: 780368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gonadotropin subunit messenger RNA concentrations after blockade of gonadotropin-releasing hormone action: testosterone selectively increases follicle-stimulating hormone beta-subunit messenger RNA by posttranscriptional mechanisms.
    Paul SJ; Ortolano GA; Haisenleder DJ; Stewart JM; Shupnik MA; Marshall JC
    Mol Endocrinol; 1990 Dec; 4(12):1943-55. PubMed ID: 1707128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The direct pituitary effect of testosterone to inhibit gonadotropin secretion in men is partially mediated by aromatization to estradiol.
    Bagatell CJ; Dahl KD; Bremner WJ
    J Androl; 1994; 15(1):15-21. PubMed ID: 8188534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of changing gonadotropin-releasing hormone pulse frequency on puberty.
    Bridges NA; Hindmarsh PC; Matthews DR; Brook CG
    J Clin Endocrinol Metab; 1994 Sep; 79(3):841-7. PubMed ID: 8077371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The stimulatory and down-regulatory effects of a gonadotropin-releasing hormone agonist in man.
    Heber D; Bhasin S; Steiner B; Swerdloff RS
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1084-8. PubMed ID: 6233295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin-releasing hormone agonists are unsuccessful in reducing tumoral gonadotropin secretion in two patients with gonadotropin-secreting pituitary adenomas.
    Sassolas G; Lejeune H; Trouillas J; Forest MG; Claustrat B; Lahlou N; Loras B
    J Clin Endocrinol Metab; 1988 Jul; 67(1):180-5. PubMed ID: 2967850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation of male hypogonadotropic hypogonadism and constitutional delay of puberty by pulsatile administration of gonadotropin-releasing hormone.
    Partsch CJ; Hermanussen M; Sippell WG
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1196-203. PubMed ID: 3923024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prolonged pulsatile administration of luteinizing hormone-releasing hormone in prepubertal children: diagnostic and physiologic aspects.
    Delemarre-van de Waal HA; Van den Brande JL; Schoemaker J
    J Clin Endocrinol Metab; 1985 Nov; 61(5):859-67. PubMed ID: 3930552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.